Contact us

7 Results:

Sort By:

Research Suggests Some Premature Infants May Go Home from the NICU Up to 3 Weeks Earlier When Fed Prolacta’s 100% Human Milk-Based Nutritional Products; Those with Bronchopulmonary Dysplasia May Benefit the Most

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD) Length of hospital stay

Benefits of an Exclusive Human Milk Diet Extend Beyond Reduction of NEC, Finds New Study Published in the Journal Breastfeeding Medicine

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies Necrotizing Entercolitis (NEC) Retinopathy of Prematurity (ROP)

Multiple NICUs Showed Improved Growth & Lung Health in Premature Infants by Fortifying Feeds Safely in the First Days of Life with Prolacta’s 100% Human Milk-Based Fortifiers

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD) Early Fortification Feeding Protocols Growth Necrotizing Entercolitis (NEC) Product

Understanding Bronchopulmonary Dysplasia (BPD)

Type: Blog

Topic(s): Bronchopulmonary Dysplasia (BPD)

Donor Human Milk Protects Against Bronchopulmonary Dysplasia | Latch

Type: Blog

Topic(s): Bronchopulmonary Dysplasia (BPD) Feeding Intolerance Feeding Protocols Healthcare Professionals

Economic Benefits and Costs of Human Milk Feedings | Latch

Type: Blog

Topic(s): Bronchopulmonary Dysplasia (BPD) Late-Onset Sepsis Necrotizing Entercolitis (NEC) Neurodevelopmental Outcomes

Clinical Trial Evaluating the Effect of Prolact CR® on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth Weight Infants Surpasses the Halfway Point

Type: Press Releases

Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies on Prolact/Humavant CR Length of hospital stay

Not finding the reference you’re looking for?

Email us at info@prolacta.com